![AVDL - Avadel Pharmaceuticals plc - Depositary Receipt (Common Stock) Stock - Stock Price, Institutional Ownership, Shareholders (NasdaqGM) AVDL - Avadel Pharmaceuticals plc - Depositary Receipt (Common Stock) Stock - Stock Price, Institutional Ownership, Shareholders (NasdaqGM)](https://images.fintel.io/us-avdl-put-call-ratio.png)
AVDL - Avadel Pharmaceuticals plc - Depositary Receipt (Common Stock) Stock - Stock Price, Institutional Ownership, Shareholders (NasdaqGM)
💫Huge news! Today, @fda approved a new treatment for #narcolepsy! Thank you to Avadel Pharmaceuticals and every single person who… | Instagram
![AVDL / Avadel Pharmaceuticals plc - Depositary Receipt (Common Stock) - Put/Call Ratio, Options Sentiment, Unusual Options Activity AVDL / Avadel Pharmaceuticals plc - Depositary Receipt (Common Stock) - Put/Call Ratio, Options Sentiment, Unusual Options Activity](https://images.fintel.io/us-avdl-put-call-ratio-expiry.png)
AVDL / Avadel Pharmaceuticals plc - Depositary Receipt (Common Stock) - Put/Call Ratio, Options Sentiment, Unusual Options Activity
Avadel Pharmaceuticals plc on LinkedIn: Efficacy of once-nightly sodium oxybate (FT218) in narcolepsy type 1 and…
![Exclusive License Agreement by and between Perrigo Pharma International | AVADEL PHARMACEUTICALS PLC | Business Contracts | Justia Exclusive License Agreement by and between Perrigo Pharma International | AVADEL PHARMACEUTICALS PLC | Business Contracts | Justia](https://resources.contracts.justia.com/contract-images/f337b0df6a799923e4810b28cef70d51cd70f5e3.jpg)
Exclusive License Agreement by and between Perrigo Pharma International | AVADEL PHARMACEUTICALS PLC | Business Contracts | Justia
![Avadel Pharmaceuticals Announces Strong LUMRYZ Launch Performance and Provides Preliminary Fourth Quarter and Full Year 2023 Financial Highlights | AVDL Stock News Avadel Pharmaceuticals Announces Strong LUMRYZ Launch Performance and Provides Preliminary Fourth Quarter and Full Year 2023 Financial Highlights | AVDL Stock News](https://static.stocktitan.net/company-logo/AVDL-lg.webp)
Avadel Pharmaceuticals Announces Strong LUMRYZ Launch Performance and Provides Preliminary Fourth Quarter and Full Year 2023 Financial Highlights | AVDL Stock News
![Avadel Pharmaceuticals plc: Annual Report for Fiscal Year Ending December 31, 2022 (Form 10-K) - MoneyController (ID 1246582) Avadel Pharmaceuticals plc: Annual Report for Fiscal Year Ending December 31, 2022 (Form 10-K) - MoneyController (ID 1246582)](https://www.moneycontroller.co.uk/upload/aziende/avadel-pharmaceuticals-plc_20210803102258.jpg)